The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immune profiling of pre- and post-treatment breast cancer tissues from the S0800 randomized neoadjuvant trial of weekly nab-paclitaxel with or without bevacizumab and dose dense doxorubicin and cyclophosphamide.
 
Xiaotong Li
No Relationships to Disclose
 
Sarah Warren
Employment - NanoString Technologies
Stock and Other Ownership Interests - NanoString Technologies
Consulting or Advisory Role - Roche
Travel, Accommodations, Expenses - Roche
 
Vasiliki Pelekanou
No Relationships to Disclose
 
Vikram Wali
No Relationships to Disclose
 
Alessandra Cesano
Employment - NanoString Technologies
Stock and Other Ownership Interests - NanoString Technologies
 
Mingdong Liu
Employment - NanoString Technologies
Stock and Other Ownership Interests - NanoString Technologies
 
Patrick Danaher
Employment - NanoString Technologies
Stock and Other Ownership Interests - NanoString Technologies
 
Nathan Elliott
Patents, Royalties, Other Intellectual Property - NanoString Technologies; NanoString Technologies (Inst)
 
Zeina A. Nahleh
No Relationships to Disclose
 
Daniel F. Hayes
Stock and Other Ownership Interests - InBiomotion; OncImmune
Consulting or Advisory Role - Cepheid
Research Funding - AstraZeneca (Inst); Lilly (Inst); Menarini (Inst); Merrimack (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Circulating Tumor Cell Capturing Techniques and Devices. Patent No.: US 8,951,484 B2. Date of Patent: Feb. 10, 2015. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Diagnosis and Treatment of Breast Cancer. Patent No. US 8,790,878 B2. Date of Patent: Jul. 29, 2014. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Royalties from licensed technology.; Title: A method for predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells. Patent no. 05725638.0-1223-US2005008602.
Other Relationship - Menarini
 
Gabriel N. Hortobagyi
Consulting or Advisory Role - Agendia; Bayer; Lilly; Merck; Novartis; Peregrine Pharmaceuticals; Roche
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
William E. Barlow
Research Funding - AstraZeneca (Inst); Merck (Inst)
 
Christos Hatzis
No Relationships to Disclose
 
Lajos Pusztai
Honoraria - Almac Diagnostics; AstraZeneca/MedImmune; Merck; Pfizer; pfizer; Syndax
Consulting or Advisory Role - H3 Biomedicine; Merck; Novartis; PierianDx; Seagen; Syndax
Research Funding - AstraZeneca; Genentech; Merck; Seagen